[Comment] Measuring success of adjuvant treatment for patients with melanoma

Most people diagnosed with melanoma have their disease successfully treated by surgery alone, but about 20% are at high risk of recurrence after surgery, with potentially life-threatening consequences. Adjuvant immunotherapy has been routinely available for this population since 2017. The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 study, which evaluated pembrolizumab, was a practice-changing trial1 underpinning a body of data supporting the role of adjuvant immune checkpoint inhibitor therapy for melanoma.